REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Key Inclusion Criteria:

1. Patients with histologically or cytologically documented squamous or non-squamous
NSCLC with stage IIIB or IIIC disease who are not candidates for treatment with
definitive concurrent chemoradiation or patients with stage IV disease if they have
not received prior systemic treatment for recurrent or metastatic NSCLC

2. Availability of an archival (≤5 months) or on-study obtained formalin-fixed,
paraffin-embedded tumor tissue sample from a metastatic or recurrent site, which has
not previously been irradiated

3. Expression of PD-L1 in <50% of tumor cells determined by the commercially available
assay performed by the central laboratory

4. At least 1 radiographically measureable lesion by computed tomography (CT) or magnetic
resonance imaging (MRI) per RECIST 1.1 criteria. Target lesions may be located in a
previously irradiated field if there is documented (radiographic) disease progression
in that site

5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

6. Anticipated life expectancy of at least 3 months

Key Exclusion Criteria:

1. Patients who have never smoked, defined as smoking ≤100 cigarettes in a lifetime

2. Active or untreated brain metastases or spinal cord compression

3. Patients with tumors tested positive for Epidermal growth factor receptor (EGFR) gene
mutations, Anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene
receptor tyrosine kinase(ROS1) fusions

4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to enrollment

5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing
pneumonia), of active, noninfectious pneumonitis that required immune-suppressive
doses of glucocorticoids to assist with management, or of pneumonitis within the last
5 years

6. Ongoing or recent evidence of significant autoimmune disease that required treatment
with systemic immunosuppressive treatments, which may suggest risk of immune-related
treatment-emergent adverse events (irTEAEs)

7. Previous treatment with idelalisib at any time (ZYDELIG®)

8. Patients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or
equivalent) within 14 days of randomization

Note: Other protocol defined Inclusion/Exclusion criteria may apply